Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $11.54 in the prior trading day, Olema Pharmaceuticals Inc (NASDAQ: OLMA) closed at $11.48, down -0.52%. In other words, the price has decreased by -$0.52 from its previous closing price. On the day, 0.59 million shares were traded. OLMA stock price reached its highest trading level at $12.6 during the session, while it also had its lowest trading level at $11.47.
Ratios:
Our goal is to gain a better understanding of OLMA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.10 and its Current Ratio is at 7.10. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on April 02, 2024, initiated with a Buy rating and assigned the stock a target price of $24.
On January 30, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $20.
On July 21, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $21.Oppenheimer initiated its Outperform rating on July 21, 2023, with a $21 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’24 when Paradigm Biocapital Advisors L sold 2,400,000 shares for $14.91 per share. The transaction valued at 35,796,000 led to the insider holds 783,118 shares of the business.
Harmon Cyrus sold 4,066 shares of OLMA for $63,348 on Jul 29 ’24. The Director now owns 752,217 shares after completing the transaction at $15.58 per share. On Jul 30 ’24, another insider, Harmon Cyrus, who serves as the Director of the company, sold 934 shares for $15.55 each. As a result, the insider received 14,524 and left with 751,283 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OLMA now has a Market Capitalization of 660279040 and an Enterprise Value of 442613984.
Stock Price History:
Over the past 52 weeks, OLMA has reached a high of $17.23, while it has fallen to a 52-week low of $8.51. The 50-Day Moving Average of the stock is -5.00%, while the 200-Day Moving Average is calculated to be -5.64%.
Shares Statistics:
The stock has traded on average 460.67K shares per day over the past 3-months and 408550 shares per day over the last 10 days, according to various share statistics. A total of 54.99M shares are outstanding, with a floating share count of 49.24M. Insiders hold about 14.02% of the company’s shares, while institutions hold 91.28% stake in the company. Shares short for OLMA as of 1730332800 were 8309802 with a Short Ratio of 18.04, compared to 1727654400 on 8511108. Therefore, it implies a Short% of Shares Outstanding of 8309802 and a Short% of Float of 25.2.
